HbA1c: What This Test Actually Measures

The Biochemistry Behind the Number

HbA1c measures a specific, irreversible chemical reaction between glucose and the beta chain of hemoglobin A. When glucose circulates in your bloodstream, it attaches to hemoglobin through a non-enzymatic process called glycation. The higher your average blood glucose, the greater the percentage of hemoglobin molecules that become glycated [1].

This reaction is not random. Glucose binds preferentially to the N-terminal valine residue on hemoglobin's beta chain, forming an unstable Schiff base (sometimes called "labile A1c") that rearranges over hours into a stable ketoamine called HbA1c [2]. That stability is the reason the test works. Once formed, HbA1c persists for the remaining lifespan of the red blood cell.

A single red blood cell circulates for approximately 120 days before the spleen removes it. The HbA1c value at any given blood draw therefore represents a weighted average of glucose exposure, with the most recent 30 days contributing roughly 50% of the signal and days 60 to 120 contributing progressively less [3]. This weighting matters clinically: a patient who dramatically improves diet and starts semaglutide will see HbA1c begin to shift within 4 to 6 weeks, not 3 full months.

Modern clinical labs measure HbA1c using high-performance liquid chromatography (HPLC) or immunoassay methods standardized to the National Glycohemoglobin Standardization Program (NGSP) reference [4]. Point-of-care devices use boronate affinity or immunoassay and can deliver results in under 5 minutes.

Normal, Prediabetes, and Diabetes Ranges

The American Diabetes Association (ADA) defines three diagnostic categories based on HbA1c [5]. Below 5.7% is normal. Between 5.7% and 6.4% indicates prediabetes. At 6.5% or above, a diabetes diagnosis is confirmed when repeated on a second occasion or supported by a concurrent fasting glucose of 126 mg/dL or higher.

These thresholds are not arbitrary. The ADA adopted 6.5% after epidemiologic analyses showed that retinopathy prevalence rises sharply at and above this level. The DETECT-2 collaboration, pooling data from 44,623 participants across nine countries, found that the inflection point for moderate retinopathy occurred at an HbA1c of 6.5% (sensitivity 72%, specificity 73%) [6].

For people already diagnosed with type 2 diabetes, the ADA recommends a general target of below 7.0% (53 mmol/mol) [5]. The American Association of Clinical Endocrinology (AACE) sets a tighter target of 6.5% or below for patients who can achieve it without significant hypoglycemia [7]. Older adults or those with extensive comorbidities may have relaxed targets of 7.5% to 8.0%.

The UKPDS trial (N=3,867) demonstrated that each 1% absolute reduction in HbA1c was associated with a 37% decrease in microvascular endpoints, a 21% reduction in diabetes-related death, and a 14% reduction in myocardial infarction [8]. Those numbers remain the bedrock of glycemic target-setting three decades later.

How HbA1c Translates to Average Glucose

Clinicians often convert HbA1c to estimated average glucose (eAG) to help patients understand results in the same units their home glucometers display. The ADAG study (N=507) established the regression equation: eAG (mg/dL) = 28.7 × HbA1c − 46.7 [9].

In practical terms:

• HbA1c 5.0% corresponds to an eAG of approximately 97 mg/dL
• HbA1c 6.0% corresponds to approximately 126 mg/dL
• HbA1c 7.0% corresponds to approximately 154 mg/dL
• HbA1c 8.0% corresponds to approximately 183 mg/dL
• HbA1c 10.0% corresponds to approximately 240 mg/dL

Dr. David Nathan, principal investigator of the ADAG study at Massachusetts General Hospital, noted: "Reporting A1C results as eAG may help patients and providers better understand the A1C value and make it more actionable for day-to-day diabetes management" [9].

This conversion has limits. Two patients with identical HbA1c values of 7.0% may have very different glucose profiles. One might run steady at 150 mg/dL. The other might oscillate between 60 and 280 mg/dL, averaging out to the same number. Continuous glucose monitoring (CGM) data has made this distinction visible, which is why the 2023 ADA Standards of Care now recommend pairing HbA1c with time-in-range metrics when CGM is available [5].

When HbA1c Can Mislead

HbA1c is reliable for most patients. It can produce inaccurate results in specific clinical situations.

Hemoglobin variants. Sickle cell trait (HbAS), hemoglobin C, and hemoglobin E can interfere with certain assay methods, producing falsely high or falsely low results depending on the platform used [10]. The NGSP maintains a list of assays and their known interferences with hemoglobin variants. Clinicians ordering HbA1c for patients with known hemoglobinopathies should verify their lab's methodology.

Altered red blood cell turnover. Any condition that shortens red blood cell lifespan will lower HbA1c independent of actual glucose levels. Iron-deficiency anemia, hemolytic anemias, recent significant blood loss, and chronic kidney disease (especially with erythropoietin therapy) all fall into this category [11]. Conversely, conditions that extend red blood cell lifespan, such as splenectomy or aplastic anemia, can falsely raise HbA1c.

Recent transfusion. Receiving packed red blood cells dilutes the patient's glycated hemoglobin with donor hemoglobin, producing unreliable results for 8 to 12 weeks after transfusion [10].

Pregnancy. Physiologic hemodilution in the second and third trimesters lowers HbA1c. The ADA recommends using fasting and postprandial glucose targets rather than HbA1c alone for managing gestational diabetes [5].

Race and ethnicity. At matched glucose levels measured by CGM, Black individuals tend to have HbA1c values 0.3 to 0.4 percentage points higher than white individuals [12]. A 2017 study in Annals of Internal Medicine (N=2,233) found that this glycation gap persisted after adjusting for socioeconomic factors and glucose exposure. This disparity has prompted debate about whether HbA1c thresholds should be race-adjusted. The ADA currently does not recommend race-specific thresholds but advises clinicians to be aware of the discrepancy [5].

HbA1c for Diabetes Screening

The U.S. Preventive Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 who have overweight or obesity, assigning this a grade B recommendation [13]. HbA1c is one of three accepted screening methods alongside fasting plasma glucose and the 2-hour oral glucose tolerance test (OGTT).

HbA1c has practical advantages for screening. It requires no fasting, shows lower day-to-day biological variability than fasting glucose (coefficient of variation <2% vs. 5 to 8% for fasting glucose), and reflects chronic rather than acute glycemic status [4]. Its main disadvantage is cost: an HbA1c assay typically runs $20 to $50, compared with $5 to $15 for a fasting glucose.

The Diabetes Prevention Program (DPP) trial (N=3,234) showed that among participants with prediabetes, intensive lifestyle intervention reduced the risk of progressing to type 2 diabetes by 58% over 2.8 years [14]. The drug arm using metformin 850 mg twice daily reduced progression by 31%. These results remain the foundation of the clinical response to a prediabetes-range HbA1c.

Dr. Robert Ratner, former Chief Scientific and Medical Officer of the ADA, stated: "An A1C of 5.7 to 6.4 percent should be treated as a call to action, not a wait-and-see result" [7].

HbA1c in GLP-1 Receptor Agonist Monitoring

For patients starting semaglutide, tirzepatide, or other GLP-1 receptor agonists, HbA1c is the primary metric for tracking glycemic response over time. Baseline HbA1c guides initial prescribing decisions, and repeat testing at 3-month intervals confirms whether the medication is reaching its target.

The SURPASS-1 trial (N=478) of tirzepatide monotherapy showed HbA1c reductions from a baseline of 7.94% to 5.68% at the 15 mg dose after 40 weeks, a 2.07 percentage-point absolute drop [15]. In SUSTAIN-6 (N=3,297), semaglutide 1.0 mg reduced HbA1c by 1.4 percentage points from a baseline of 8.7% at 104 weeks, with cardiovascular event reduction as a co-primary endpoint [16].

These trials also revealed something about HbA1c's kinetics during GLP-1 therapy. The steepest HbA1c decline typically occurs in the first 12 to 16 weeks. Patients who do not achieve at least a 0.5 percentage-point reduction by week 12 on an adequate dose may benefit from combination therapy or dose escalation [7].

For GLP-1 medications prescribed primarily for weight management (semaglutide 2.4 mg as Wegovy), monitoring HbA1c still adds value. The STEP-1 trial (N=1,961) enrolled participants without diabetes and found that semaglutide 2.4 mg reduced HbA1c from a mean baseline of 5.7% to 5.3% at 68 weeks [17]. Tracking this metric can identify patients drifting toward prediabetes or confirm that weight loss is improving insulin sensitivity.

How to Lower HbA1c

Lowering HbA1c requires sustained reduction of average blood glucose through a combination of medication, dietary modification, and physical activity. The magnitude of reduction depends on starting HbA1c and the interventions used.

Medications. Metformin alone typically reduces HbA1c by 1.0 to 1.5 percentage points [18]. GLP-1 receptor agonists add 1.0 to 2.0 additional percentage points. SGLT2 inhibitors (empagliflozin, dapagliflozin) contribute 0.5 to 0.8 percentage points. Insulin therapy, when needed, has no ceiling effect and can bring HbA1c to target in virtually any patient if dosed appropriately.

Dietary changes. A 2019 systematic review in the BMJ (23 trials, N=4,990) found that low-carbohydrate diets (<130 g/day) reduced HbA1c by 0.47 percentage points more than higher-carbohydrate control diets at 6 months [19]. Mediterranean dietary patterns showed similar magnitude improvements in the PREDIMED trial.

Physical activity. A Cochrane review of 47 trials (N=8,538) found that structured exercise programs reduced HbA1c by 0.6 percentage points compared with usual care, with both aerobic and resistance training contributing [20]. The effect was independent of weight loss, suggesting that muscle glucose uptake during exercise directly lowers average glycemia.

Combined approach. The Look AHEAD trial (N=5,145) demonstrated that intensive lifestyle intervention combining caloric restriction and 175 minutes per week of moderate activity reduced HbA1c by 0.6 percentage points more than the control group at year one [21].

Clinicians typically recheck HbA1c 3 months after initiating or changing therapy. A result still above target after two consecutive checks at adequate doses triggers the next step in the treatment algorithm.

Can HbA1c Be Too Low?

Yes. An HbA1c below 4.0% is unusual and warrants investigation. Very low values may indicate hemolytic anemia, chronic blood loss, or a hemoglobin variant interfering with the assay rather than true euglycemia [10].

In patients on insulin or sulfonylureas, an HbA1c below 6.0% raises concern for recurrent hypoglycemia. The ACCORD trial (N=10,251) tested whether targeting HbA1c below 6.0% in type 2 diabetes would reduce cardiovascular events. The intensive-therapy arm was stopped early after 3.5 years because of a 22% increase in all-cause mortality (hazard ratio 1.22 to 95% CI 1.01 to 1.46) [22]. Severe hypoglycemia was three times more common in the intensive group.

This finding reshaped clinical practice. The ADA now specifies that targets should be individualized and that aggressive lowering below 6.5% should only be pursued when it can be achieved "without significant hypoglycemia or other adverse effects of treatment" [5]. For older adults (age 65 and above) with multiple comorbidities, the ADA suggests HbA1c targets of 7.5% to 8.0%.

How Often Should HbA1c Be Tested?

The ADA recommends HbA1c testing at least twice per year for patients meeting treatment goals and quarterly (every 3 months) for patients whose therapy has changed or who are not at target [5]. For screening purposes in adults without diabetes, repeat testing every 3 years is appropriate if the initial result is normal, or annually if in the prediabetes range [13].

Testing more frequently than every 8 weeks is generally uninformative because the red blood cell turnover kinetics mean the result will still reflect significant overlap with the prior measurement window. An exception is pregnancy, where more frequent monitoring with alternative markers (fructosamine, glycated albumin) may be appropriate [5].

Insurance coverage for HbA1c testing is broad. Medicare covers the test up to four times per year for beneficiaries with diabetes and once for screening in eligible adults. Most commercial plans follow similar coverage rules without prior authorization.